CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory Large B-cell Lymphoma

Large B cell lymphoma is a common type of non-Hodgkin lymphoma, a cancer that starts in certain cells of the immune system. While many patients respond well to initial treatment, some experience a return or worsening of the disease, known as relapsed or refractory Large B cell lymphoma. Current treatments for this condition have limited effectiveness, highlighting the need for new approaches. One such approach is CAR-T cell therapy, which involves modifying the patient's own immune cells to better recognize and fight cancer cells. This study focuses on a specific type of CAR-T cell therapy that targets two proteins, CD19 and CD22, found on the surface of lymphoma cells. By targeting both proteins, this therapy aims to provide a more comprehensive treatment for patients with relapsed or refractory Large B cell lymphoma. In this phase 2 clinical trial, participants will receive the CD19/CD22 bispecific CAR-T cell therapy. The main goal is to evaluate the therapy's effectiveness, measured by the best overall response rate three months after the infusion of the CAR-T cells. This response rate includes both complete responses, where all signs of cancer disappear, and partial responses, where the cancer shrinks but does not completely disappear. The study also aims to assess the safety of this treatment.